Medication Monitor



Generic Name (Trade Name—Company)
Notes
February 12, 2018

Vancomycin hydrochloride for oral solution

(Firvanq—CutisPharma)
Oral liquid therapy of vancomycin approved for CDAD

FDA approved vancomycin hydrochloride for oral solution (Firvanq—CutisPharma) for the treatment of Clostridium difficile–associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. It was designed to be an easy-to-use, cost-effective alternative to existing vancomycin therapies.

The product will be available in April 2018 in 25-mg/mL and 50-mg/mL strengths in 150-mL and 300-mL sizes.